|Solubility:||DMSO up to 50 mM|
|Storage:||Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.|
Rapamycin is a potent and selective mTOR inhibitor. Rapamycin, in complex with the cytosolic protein FK-binding protein 12 (FKBP12), inhibits mTOR Complex 1 (mTORC1) by binding to the FRB domain of mTor. Given the central roles mTor plays, Rapamycin showed diverse activities, including anti-proliferative effects in cancer cells, immunosuppressive effect, lifespan extension in mice, improved cognition in the mouse model of autism and Alzheimer, and inducing autophagy.
How to Use:
- In vitro: Rapamycin is usually used at 1 µM final concentration in vitro and in cellular assays.
- In vivo: Rapamycin could be orally administrated to mice at 5-20 mg/kg once per day.
- Vézina C, et al. Rapamycin (AY-22,989), a new antifungal antibiotic. (1975) J. Antibiot. 28 (10): 721.
- Heitman J, et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. (1991) Science. 253: 905-909.
- Price DJ, et al. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. (1992) Science. 257: 973-977.
- Wells AD, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. (1999) Nat. Med.5:1303-1307.
- Wendel HG, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. (2004) Nature 428 (6980): 332–7.
- Ehninger D, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. (2008) Nat. Med. 14 (8): 843–8
- Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. (2009) Nature 460 (7253): 392–5.
Products are for research use only. Not for human use.